HT
VRDN icon

Headlands Technologies’s Viridian Therapeutics VRDN Stock Holding History

Headlands Technologies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$855K Buy
46,544
+13,321
+40% +$215K 0.09% 282
2026
Q1 		$650K Buy
+33,223
New +$987K 0.07% 302
2024
Q3 		– Sell
-596
Closed -$7.75K – 1570
2024
Q2 		$7.75K Buy
596
+354
+146% +$4.9K ﹤0.01% 986
2024
Q1 		$4.24K Buy
+242
New +$4.69K ﹤0.01% 1115

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Headlands Technologies's VRDN Position: Q2 2026 in Review

Headlands Technologies increased its Viridian Therapeutics (VRDN) stake by 40% in Q2 2026, buying an estimated $215K and bringing the position to 46,544 shares worth $855K. The position accounts for 0.09% of the portfolio, ranked #282.

Headlands Technologies first reported a position in VRDN in Q1 2024 and has held it in 4 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Headlands Technologies held 46,544 shares of Viridian Therapeutics worth $855K as of Q2 2026.
  • Headlands Technologies bought 13,321 Viridian Therapeutics shares in Q2 2026, an estimated $215K.
  • Viridian Therapeutics made up 0.09% of Headlands Technologies's portfolio in Q2 2026, its #282 holding.
  • Headlands Technologies first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.